432 related articles for article (PubMed ID: 34675936)
1. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
Front Immunol; 2021; 12():757047. PubMed ID: 34675936
[TBL] [Abstract][Full Text] [Related]
2. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
[TBL] [Abstract][Full Text] [Related]
3. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
5. FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC.
Liu J; Ouyang Y; Xia Z; Mai W; Song H; Zhou F; Shen L; Chen K; Li X; Zhuang SM; Liao J
Cell Oncol (Dordr); 2024 Apr; 47(2):623-638. PubMed ID: 37856075
[TBL] [Abstract][Full Text] [Related]
6. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
Front Immunol; 2022; 13():969034. PubMed ID: 36466881
[TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma.
Borgmann M; Oetting A; Meyer F; Möckelmann N; Droste C; von Bargen CM; Möller-Koop C; Witt M; Borgmann K; Rothkamm K; Betz C; Münscher A; Clauditz TS; Rieckmann T
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3383-3393. PubMed ID: 35941227
[TBL] [Abstract][Full Text] [Related]
8. LINC01123 promotes immune escape by sponging miR-214-3p to regulate B7-H3 in head and neck squamous-cell carcinoma.
Li H; Yang Z; Yang X; Zhang F; Wang J; Wu Z; Wanyan C; Meng Q; Gao W; Yang X; Wei J
Cell Death Dis; 2022 Feb; 13(2):109. PubMed ID: 35115487
[TBL] [Abstract][Full Text] [Related]
9. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():791621. PubMed ID: 35003112
[TBL] [Abstract][Full Text] [Related]
10. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive investigation into the influence of glycosylation on head and neck squamous cell carcinoma and development of a prognostic model for risk assessment and anticipating immunotherapy.
Ma H; Xiong L; Zhao B; Hahan Z; Wei M; Shi H; Yang S; Ren Q
Front Immunol; 2024; 15():1364082. PubMed ID: 38562924
[TBL] [Abstract][Full Text] [Related]
12. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
[TBL] [Abstract][Full Text] [Related]
13. Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma.
Mao L; Fan TF; Wu L; Yu GT; Deng WW; Chen L; Bu LL; Ma SR; Liu B; Bian Y; Kulkarni AB; Zhang WF; Sun ZJ
J Cell Mol Med; 2017 Sep; 21(9):2199-2210. PubMed ID: 28401653
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
15. Identification of immune-related lncRNA panel for predicting immune checkpoint blockade and prognosis in head and neck squamous cell carcinoma.
Li Q; Shen Z; Shen Y; Deng H; Shen Y; Wang J; Zhan G; Zhou C
J Clin Lab Anal; 2022 Jun; 36(6):e24484. PubMed ID: 35561269
[TBL] [Abstract][Full Text] [Related]
16. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G
Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731
[TBL] [Abstract][Full Text] [Related]
17. HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.
Chen Y; Yang J; Jin H; Wen W; Xu Y; Zhang X; Wang Y
PeerJ; 2023; 11():e16237. PubMed ID: 37842043
[TBL] [Abstract][Full Text] [Related]
18. Multiomics data analyses to identify SLC25A17 as a novel biomarker to predict the prognosis and immune microenvironment in head and neck squamous cell carcinoma.
Shi Y; Huang J; Hu Y; Shen Y
BMC Bioinformatics; 2023 Jun; 24(1):269. PubMed ID: 37386359
[TBL] [Abstract][Full Text] [Related]
19. Constructing heterogeneous single-cell landscape and identifying microenvironment molecular characteristics of primary and lymphatic metastatic head and neck squamous cell carcinoma.
Zhang J; Liu Y; Xia L; Zhen J; Gao J; Atsushi T
Comput Biol Med; 2023 Oct; 165():107459. PubMed ID: 37713790
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of the immune signature in head and neck squamous cell carcinoma.
Baysal H; Siozopoulou V; Zaryouh H; Hermans C; Lau HW; Lambrechts H; Fransen E; De Pauw I; Jacobs J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; De Waele J; Wouters A
Front Immunol; 2022; 13():1001161. PubMed ID: 36268020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
